talazoparib plus enzalutamide: talapro-2 results and subset analyses
Published 8 months ago • 62 plays • Length 6:35Download video MP4
Download video MP3
Similar videos
-
8:56
talapro-2: phase 3 results of talazoparib plus enzalutamide for mcrpc
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
11:19
drs. fizazi, wallis on updated data from talapro-2
-
8:00
how has talapro-2 changed the standard of care for first-line mcrpc with hrr mutations?
-
1:44
talapro-2: exposure-safety of talazoparib enzalutamide in mcrpc
-
8:25
radical prostatectomy for basic teal prostate cancer | prostate cancer staging guide
-
13:24
enzalutamide approved for prostate cancer with biochemical recurrence: stephen freedland, md
-
7:00
comparing the second generation hormone therapies | ask a prostate expert, mark scholz, md
-
6:54
talapro-2: toxicities and treatment duration
-
5:01
talazoparib plus enzalutamide shows improvement in pfs over soc in first-line hrr mcrpc
-
18:58
talapro-2 study of talazoparib/enzalutamide in prostate cancer: stephen freedland and neeraj agarwal
-
14:30
mcrpc care: reducing progression risk by combining enzalutamide and talazoparib
-
1:19
talapro-2: exploratory analyses of hrr gene subgroups in mcrpc
-
38:47
uromigos live 2023: where do we stand with parp inhibitors in prostate cancer?
-
1:38
novel combination therapy regimen shows promising results for prostate cancer
-
14:39
new fda approved parp inhibitor: talzenna (talazoparib) & xtandi | #markscholzmd #alexscholz #pcri
-
2:17
enzalutamide for biochemically recurrent prostate cancer | nejm
-
1:33
the toparp-a trial
-
0:56
dr. trabulsi defines locally advanced prostate cancer
-
6:42
titan trial
-
6:05
enzamet trial
-
10:47
therap trial